Estonja - Estonjan - Ravimiamet

sandoz pharmaceuticals d.d. - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 100tk; 1000mg+50mg 180tk; 1000mg+50mg 168tk; 1000mg+50mg 7tk; 1000mg+50mg 50tk; 1000mg+50mg 28tk

Estonja - Estonjan - Ravimiamet

sandoz pharmaceuticals d.d. - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 112tk; 1000mg+50mg 100tk; 1000mg+50mg 60tk; 1000mg+50mg 196tk

Estonja - Estonjan - Ravimiamet

sandoz pharmaceuticals d.d. - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 100tk; 850mg+50mg 28tk; 850mg+50mg 196tk

Estonja - Estonjan - Ravimiamet

teva gmbh - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 14tk; 1000mg+50mg 98tk; 1000mg+50mg 28tk; 1000mg+50mg 60tk; 1000mg+50mg 112tk

Estonja - Estonjan - Ravimiamet

teva gmbh - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 28tk; 850mg+50mg 60tk; 850mg+50mg 196tk; 850mg+50mg 14tk; 850mg+50mg 112tk; 850mg+50mg 56tk; 850mg+50mg 98tk

Estonja - Estonjan - Ravimiamet

london north west university healthcare nhs trust - vaskhistidiin - süstelahus - 500mcg 1ml 1ml 10tk

Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

accord healthcare s.l.u. - buprenorphine hydrochloride, naloxone hydrochloride dihydrate - opioidiga seotud häired - muud närvisüsteemi ravimid - opioidide ravivastuse asendusravi meditsiinilise, sotsiaalse ja psühholoogilise ravi raamistikus. naloksooni komponendi eesmärk on ära hoida intravenoosset väärkasutamist. ravi on ette nähtud kasutamiseks täiskasvanutel ja üle 15-aastastel noorukitel, kes on nõustunud sõltuvuse raviks.

Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastilised ained - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

gilead sciences international ltd  - emtricitabine, rilpivirine hydrochloride, tenofovir disoproxil fumarate - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - eviplera on näidustatud täiskasvanute nakatunud inimese immuunpuudulikkuse viiruse tüüp 1 (hiv-1) ilma teadaolevate resistentsusega seotud mittenukleosiidsed pöördtranskriptaasi inhibiitorite (nnrti) klassi, tenofoviiri või emtritsitabiini, ja koos nakkav laadida ≤ 100 000 hiv-1 rna koopiat/ml. nagu teistegi retroviiruse vastaste ravimite puhul, peaks eviplera kasutamine viitama genotüpilise resistentsustestidele ja / või ajaloolistele resistentsuse andmetele..